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Background: The procoagulant state in cancer increases the thrombotic risk, but also supports tumor progression.
To investigate the molecular mechanisms controlling cancer and hemostasis, we conducted a case-control study of
genotypic and phenotypic variables of the tissue factor (TF) pathway of coagulation in breast cancer.
Methods: 366 breast cancer patients and 307 controls were genotyped for SNPs (n = 41) in the F2, F3 (TF), F5, F7,
F10, TFPI and EPCR genes, and assayed for plasma coagulation markers (thrombin generation, activated protein C
(APC) resistance, D-dimer, antithrombin, protein C, protein S, and TF pathway inhibitor (TFPI)). Associations with
breast cancer were evaluated using logistic regression to obtain odds ratios (ORs) and 95% confidence intervals
(CIs), or the chi-square test.
Results: Four SNPs in F5 (rs12120605, rs6427202, rs9332542 and rs6427199), one in F10 (rs3093261), and one in
EPCR (rs2069948) were associated with breast cancer. EPCR rs2069948 was associated with estrogen receptor (ER)
and progesterone receptor (PR) positivity, while the SNPs in F5 appeared to follow hormone receptor negative and
triple negative patients. The prothrombotic polymorphisms factor V Leiden (rs6025) and prothrombin G20210A
(rs1799963) were not associated with breast cancer. High APC resistance was associated with breast cancer in both
factor V Leiden non-carriers (OR 6.5, 95% CI 4.1-10.4) and carriers (OR 38.3, 95% CI 6.2-236.6). The thrombin parameters
short lag times (OR 5.8, 95% CI 3.7-9.2), short times to peak thrombin (OR 7.1, 95% CI 4.4-11.3), and high thrombin peak
(OR 6.1, 95% CI 3.9-9.5) predicted presence of breast cancer, and high D-dimer also associated with breast cancer (OR
2.0, 95% CI 1.3-3.3). Among the coagulation inhibitors, low levels of antithrombin associated with breast cancer (OR 5.7,
95% CI 3.6-9.0). The increased coagulability was not explained by the breast cancer associated SNPs, and was unaffected
by ER, PR and triple negative status.
Conclusions: A procoagulant phenotype was found in the breast cancer patients. Novel associations with SNPs in F5,
F10 and EPCR to breast cancer susceptibility were demonstrated, and the SNPs in F5 were confined to hormone
receptor negative and triple negative patients. The study supports the importance of developing new therapeutic
strategies targeting coagulation processes in cancer.
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There is compelling evidence that blood coagulation and
tumor biology are connected through multiple patho-
physiological pathways. Disruption of the hemostatic
balance is frequently observed in several cancer types
[1-3]. The hypercoagulable state has been attributed to
an adverse effect of malignant cells expressing procoagu-
lants, but there is now evidence of a bidirectional inter-
action between cancer and coagulation [4]. Elevated
plasma levels of activated coagulation markers, such as
D-dimer, have been shown to be markers of cancer pro-
gression and poor outcome [5-7]. Plasma levels of the
coagulation inhibitors antithrombin and protein C have
been shown to decrease, while tissue factor (TF) path-
way inhibitor (TFPI) was found to increase during can-
cer progression [8,9], and several studies have shown
that cancer patients acquire activated protein C (APC)
resistance [2,3,10,11].
During carcinogenesis a transcriptional program indu-
cing expression of hemostatic genes is turned on [12].
Procoagulants produced by tumor- and stimulated host
cells not only contribute to the increased risk of cancer-
associated thrombosis, but can also trigger cancer- sig-
naling pathways. Coagulation independent signaling in-
creases the angiogenic and metastatic behavior of tumor
cells and thereby accelerates the growth and spread of
cancer. One of the most extensively studied procoagu-
lants involved in cancer is TF. Induced by oncogenes,
such as K-ras and the epidermal growth factor receptor
(EGFR), TF is overexpressed in many cancers. TF expres-
sion has been shown to correlate with tumor progression
and poor survival [13]. TF initiates the coagulation cas-
cade by forming a complex with activated factor VII
(FVIIa), which activates factor X (FX). The assembly of
FXa with its activated cofactor, factor Va (FVa), leads to
the generation of thrombin, fibrin formation and platelet
activation. The activity of FXa and the TF/FVIIa catalytic
complex is modulated by TFPI. In addition to coagulation
activation, the TF complexes (TF/FVIIa and TF/FVIIa/
FXa) may elicit G-protein coupled intracellular signaling
mediated by protease- activated receptors (PARs). Activa-
tion of PAR-1 and PAR-2 results in expression of genes
promoting angiogenesis, cell migration, proliferation, and
metastasis [14]. Recently, it was demonstrated that the
endothelial protein C receptor (EPCR) is able to bind the
ternary TF/FVIIa/FXa complex and induce a more effi-
cient PAR-1 and PAR-2 mediated signaling in endothelial
cells [15]. EPCR positive breast cancer cells have an in-
creased ability to form tumors in vivo [16].
The F5 rs6025 and F2 rs1799963 (commonly known
as the factor V Leiden and the prothrombin G20210A
polymorphisms, respectively) are well-established pro-
coagulant polymorphisms that increase the risk of ven-
ous thrombosis, due to induction of APC resistance andincreased levels of prothrombin, respectively. Mozsik
et al. recently reported an association of factor V Leiden
with gastrointestinal cancer [17], whereas Vossen et al.
found a 6-fold increased risk of colorectal cancer for
homozygous, but not for heterozygous factor V Leiden
carriers [18]. Additional studies (across populations) on
several cancer types have also failed to show an associ-
ation with factor V Leiden heterozygotes [3,19-22]. Ex-
cept for Pihusch et al. [20], several studies have not been
able to find an increased prevalence of the prothrombin
G20210A polymorphism in cancer [3,18,19,21,22].
The F7 gene polymorphism -402GA (rs510317) has
been reported to be associated with breast cancer [23].
Still, limited information on the role of polymorphisms
in hemostatic genes to cancer pathogenesis is available,
in particular regarding the more common variants.
Breast cancer is a highly heterogenous disease with
substantial variation at both the clinical and the molecu-
lar level. Immunohistochemical expression of the growth
regulating hormone receptors; estrogen receptor (ER)
and progesterone receptor (PR), in addition to overex-
pression and/or amplification of the oncogene human
epidermal growth factor receptor 2 (HER2) are clinically
relevant markers for prognostic and predictive purposes.
The majority of breast tumors (~80%) show hormone
receptor positivity and are likely to respond to endocrine
(hormonal) therapy. 10-15% of breast cancers belong to
a subgroup called triple negative breast cancers, defined
by lack of ER, PR and HER2 overexpression. Triple
negative breast cancers tend to have poor prognosis, and
currently, no targeted therapy has been approved for this
type of breast cancer [24].
In the present case-control study, we aimed to investi-
gate the role of common single nucleotide polymor-
phisms (SNPs) in genes involved in the TF pathway of
coagulation (i.e., the F2, F3 (TF) F5, F7, F10, EPCR, and
TFPI genes) on the susceptibility of breast cancer. In
addition, markers of coagulation activity and plasma
levels of coagulation inhibitors were measured, related
to presence of breast cancer, and correlated to genotypes
of breast cancer associated SNPs.
Methods
Patient material; cases and controls
The study comprised of 385 stage I or II female breast
cancer patients (cases) enrolled between June 2008 and
August 2010 at the Oslo University Hospital Ullevål,
Oslo, and the Akershus University Hospital, Nordbyhagen,
Norway. The cases were subjected to primary breast sur-
gery (mastectomy or lumpectomy) without receiving any
pre-operative treatment, and blood samples were drawn
immediately before surgery. Cases that later were ac-
knowledged to have metastatic disease were excluded. The
controls comprised of 353 healthy women, who were
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venous thrombosis in pregnancy [25]. ER and PR status of
the tumors were determined by immunohistochemistry
and collected from pathology reviews, and tumor cell nu-
clei were scored according to pathology guidelines. HER2
status was determined by immunohistochemistry and/or
by silver enhancement in situ hybridization (SISH) (Roche,
Dual SISH HER-2) where a HER2 gene/centrosome 17
(CEP17) ratio of >2.2 defined HER2 positivity.
We excluded subjects who were not of Scandinavian
descent (i.e., not from Norway, Sweden or Denmark)
from genotypic and phenotypic analyzes, and subjects
who were pregnant, or received anticoagulant- or hor-
mone replacement therapy were excluded from the
phenotypic analyzes. After excluding one case with me-
tastases at the time of diagnosis, two cases that proved
not to have breast cancer, and 16 non-Scandinavians, the
final case group comprised of 366 breast cancer patients
for both genotypic and phenotypic analyzes. Among the
353 control subjects, 46 were non-Scandinavian, thus
leaving 307 controls for genotypic analyzes (i.e. SNPs).
34 controls were either pregnant or used oral contracep-
tives leaving 273 controls for phenotypic analyzes (i.e.
hemostatic parameters). The average age at blood sam-
pling was 57.7 (±11.2) (range 29-87) years for cases, and
40.0 (±5.6) (range 22-58) years for controls.
The Regional Committee for Medical and Health Re-
search Ethics of South-East Norway approved the study
(approval number 1.2006.1607, amendment 1.2007.1125
for Ullevål patients and 429-04148 for Akershus pa-
tients) and all included women gave their written in-
formed consent to participate.
Blood sampling
Venous blood samples were collected in Vacutainer vac-
uum tubes (Becton-Dickinson, Plymouth, UK) containing
0.5 mL buffered sodium citrate (0.129 mol/L). Whole
blood was centrifuged for 15 min at 2000 g at room tem-
perature within 1 hour to prepare platelet poor plasma,
and aliquots were stored at -70°C until analyzed. Using the
same blood collection procedure as described, plasma
from 21 healthy subjects (9 men and 12 women, mean
age 43 years) were collected to create a pooled normal
plasma (PNP) reference. None of these 21 subjects had
antithrombin-, protein C- or protein S deficiencies, were
carriers for the factor V Leiden or the prothrombin
G20210A polymorphisms, tested positive for antiphospho-
lipid antibodies (lupus anticoagulant, or anticardiolipin- or
anti-β2-glycoprotein 1 antibodies), and they did not use
oral contraceptives or any other hormones.
Phenotypic hemostatic parameters
The endogenous thrombin potential (ETP) was mea-
sured using the Calibrated Automated Thrombogram(CAT) assay [26], according to the manufacturer’s instruc-
tions (Thrombinoscope B.V, Maastricht, the Netherlands).
Four thrombin generation parameters were recorded; ETP
(time integral of the thrombin formation), lag time, peak
thrombin (Peak), and time to peak thrombin (ttPeak).
APC resistance was determined after the addition of APC
(American Diagnostica Inc., Stamford, CT, USA), and the
results were reported as APC-sensitivity ratio (APC-sr);
which is the ratio of ETP in presence of APC divided by
ETP in absence of APC normalized against the similar ra-
tio obtained with PNP measured in the same run [25].
The coagulation inhibitors antithrombin and protein C ac-
tivities, and free protein S antigen, were analyzed using the
Chromogenix Coamatic® Antithrombin, the Chromogenix
Coamatic® Protein C, and the Chromogenix Coamatic®
Protein S-Free kits from Instrumentation Laboratory
(Lexington, MA, USA). Free TFPI antigen and D-dimer
were analyzed by the commercial enzyme-linked immuno-
sorbent assay kits Asserachrom® Free TFPI and Assera-
chrom® D-DI from Diagnostica Stago, Asnières, France.
The hemostatic parameters are shown in Additional file 1:
Figure S1.DNA isolation and genotyping
DNA was either isolated on the BioRobot Universal with
the QIAamp DNA Blood BioRobot MDx Kit (Qiagen,
Hilden, Germany) and eluted in Qiagen buffer AE
(10 mM Tris-Cl 0.5 mM EDTA; pH 9.0), or with the
Gentra Autopure LS machine using the Puregene Gen-
omic DNA purification Kit (Gentra Systems, Minneapolis,
MN 55441 USA), or manually using the MasterPure TM
DNA Purification Kit for Blood Version II (Epicentre® Bio-
technologies, Madison, WI, USA). SNPs were genotyped
with the iPLEX Gold massarray platform (Sequenom) at
the Centre for Integrative Genetics, Norwegian University
of Life Sciences, Ås, Norway.SNP selection and quality control
We used a SNP tagging approach to avoid genotyping
redundant SNPs. By using a minor allele frequency
(MAF) criterion of ≥10% and pairwise r2 ≥ 0.8 as a cut-
off for proxies, 39 SNPs were selected in the following
gene regions: F2 (n = 3), F3 (TF) (n = 4), F5 (n = 10), F7
(n = 2), F10 (n = 9), TFPI (n = 9), and EPCR (n = 2). The
tag-SNP selection was performed using the Tagger pro-
gram (http://www.broad.mit.edu/mpg/haploview/, [27])
implemented in Haploview v. 4.2 and genotype data
from the Caucasian population (Utah residents with an-
cestry from northern and western Europe) from the
HapMap project release 27, phase III on NCBI B36 as-
sembly, dbSNPb126. Factor V Leiden (rs6025) and the
prothrombin G20210A (rs1799963) polymorphisms were
also included in the SNP selection. Hence, the final SNP
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both cases and controls.
Individuals with ≥50% missing genotypes and SNPs
with <97% call rates were excluded for further analysis.
SNPs that deviated from Hardy-Weinberg equilibrium in
the exact test were also excluded (significance threshold
P < 0.001).
One SNP failed genotyping in all individuals (TFPI
rs3213739), two SNPs had genotyping call rates <97%
(F7 rs1475931 and TFPI rs2041778), and one SNP was
out of Hardy Weinberg equilibrium in controls (EPCR
rs867186). Hence, after filtering, 37 of the 41 genotyped
SNPs remained for further analysis.
Statistical methods
All statistical analyzes were performed using SPSS statis-
tical software (version 21.0; SPSS Inc., Chicago, IL, USA)
and PLINK v.1.07 (http://pngu.mgh.harvard.edu/~purcell/
plink/).
Associations between each SNP and breast cancer
were analyzed using an allelic chi-square (χ2) test with 1
degree of freedom. The false discovery rate (FDR) pro-
cedure described by Benjamini & Hochberg [28] was
used to correct for multiple testing.
Odds ratios (ORs), 95% confidence intervals (CIs), and
P-values were determined for the genotypes of the SNPs
that were significant at the 5% level and had a FDR < 0.25
in the allelic test. Binary logistic regression under the addi-
tive risk model was applied with case/control status as the
dependent variable, and genotypes (coded 0, 1, 2 for each
extra risk allele) as the categorical independent variables.
Risk alleles were defined as the alleles being more preva-
lent among cases, thus ORs >1 were obtained.
Independence between SNP associations was tested by
conditional analysis in PLINK, where the allelic dosage
for a given SNP was added as a covariate in a binary lo-
gistic regression model (additive model). The E-M algo-
rithm was used to estimate haplotype frequencies, and
haplotype-based association analysis was conducted
using binary logistic regression (additive model). Haplo-
view v. 4.2 was used for creating linkage disequilibrium
(LD) plots, and the SNAP tool [29] was used to obtain
pair-wise LD measurements. The Alamut software (v. 2.0)
was used to predict if any of the associated SNPs, or their
proxies, could affect splicing.
The plasma levels of hemostatic parameters were com-
pared between cases and controls using t-test when nor-
mally distributed, or the non-parametric Mann-Whitney
when the distribution was skewed. Tests with P < 0.05
were considered significantly different. Logistic regres-
sion was used to determine the associations with breast
cancer status, or ER, PR, HR, and triple negative status,
for either high or low levels of each of the hemostatic
parameters. Case and control subjects were dichotomizedaccording to either the 10th or the 90th percentiles of the
hemostatic parameters’ plasma levels (defined in controls).
The group with levels above the 10th percentile or below
the 90th percentile served as the reference group.
Genotype-phenotype correlations were evaluated by
the Kruskal-Wallis test. For tests with P < 0.05, follow-up
pairwise comparisons were conducted using Mann
Whitney U testing with Bonferroni correction, and
genotype-phenotype pairs with at least one significant
pairwise test were reported. For correlations with the
APC resistant phenotype, factor V Leiden carriers were
excluded due to the established role for the factor V Leiden
variant in APC resistance.
Results
Associations between SNPs in TF pathway genes and risk
of breast cancer
Associations between SNP alleles of the TF pathway
genes and risk of breast cancer were assessed by com-
paring allele distributions between cases and controls
(Table 1). A total of six SNPs in three distinct genes ex-
hibited significantly different allele distributions with
FDR < 0.25 (four in F5: rs12120605 (P = 0.026), rs6427202
(P = 0.028), rs9332542 (P = 0.023), rs6427199 (P = 0.037),
one in F10: rs3093261 (P = 0.011), and the one in EPCR:
rs2069948 (P = 0.030)).
The genotype distributions for these six SNPs were
compared using an additive model, since the underlying
genetic model was unknown. All loci showed significant
associations also at the genotypic level, with ORs ran-
ging from 1.27 to 1.49 (Additional file 2: Table S1).
Furthermore, whereas the association with EPCR
rs2069948 was restricted to patients with ER and PR
positive tumors (OR 1.27, 95% CI 1.01-1.58; and OR
1.30, 95% CI 1.03-1.65, respectively), there was an overall
trend that the four SNPs in F5 were confined to hor-
mone receptor negative patients (ER/PR negative) (ORs
from 1.54 to 1.99) and triple negative patients (ER/PR/
HER2 negative) (ORs from 1.68 to 2.11) when compared
with healthy controls (Additional file 3: Table S2).
However, the analyzes lacked power to show significant
differences in genotype distributions between patient
subgroups.
The allele distribution for factor V Leiden was equal
among cases (3.3%) and controls (3.4%), while the pro-
thrombin G20210A polymorphism appeared more fre-
quently (non-significant) in patients (1.3%) compared to
controls (0.5%) (Table 1). Only heterozygous carriers of
either polymorphism were detected.
According to the SNAP tool, each of the F5 rs6427202,
F5 rs9332542, and EPCR rs2069948 SNPs were all in
strong or perfect LD (r2 = 0.93-1.00) with several SNPs in
the European (CEU) population. The F5 rs6427202 SNP
was in strong LD (r2 ≥ 0.96) with 20 intronic F5 SNPs,
Table 1 Allele distributions of SNPs in TF pathway genes in cases and controls











F2 11 rs2070852 46701501 Intronic C G 0.290 0.316 0.99 0.89 0.319 0.83
F2 11 rs3136516 46717332 Intronic G A 0.448 0.448 0.00 1.00 0.996 1.00
F2 11 rs5896 46701579 Coding (T > M) T C 0.133 0.127 0.09 1.05 0.760 0.93
F2 11 rs1799963 46717631 3UTR A G 0.013 0.005 2.20 2.60 0.138 0.61
F3 1 rs3917643 94774455 Intronic C T 0.058 0.080 2.58 0.70 0.109 0.57
F3 1 rs696619 94777808 Intronic A G 0.414 0.440 0.87 0.90 0.351 0.83
F3 1 rs1324214 94769876 Intronic A G 0.240 0.271 1.59 0.85 0.207 0.70
F3 1 rs3917615 94774578 Intronic T C 0.439 0.433 0.04 1.02 0.839 0.93
F5 1 rs12120605 167789178 Intronic T* G 0.140 0.100 4.93 1.47 0.026 0.22
F5 1 rs6427202 167795454 Intronic C* T 0.454 0.394 4.82 1.28 0.028 0.22
F5 1 rs9332542 167805907 Intronic A G* 0.286 0.344 5.16 0.76 0.023 0.22
F5 1 rs6427199 167790161 Intronic A G* 0.364 0.420 4.36 0.79 0.037 0.23
F5 1 rs6012 167795204 Intronic T C 0.162 0.164 0.01 0.98 0.906 0.93
F5 1 rs4524 167778379 Coding (K > R) C T 0.261 0.257 0.03 1.02 0.871 0.93
F5 1 rs4656687 167771782 Intronic C T 0.323 0.312 0.17 1.05 0.676 0.93
F5 1 rs6025 167785673 Coding (Q > R) T C 0.033 0.034 0.02 0.96 0.900 0.93
F5 1 rs9287095 167805090 Intronic A G 0.094 0.104 0.34 0.90 0.561 0.93
F5 1 rs10158595 167786988 Intronic T C 0.223 0.248 1.14 0.87 0.286 0.83
F5 1 rs9332618 167767105 Intronic A G 0.133 0.139 0.08 0.95 0.773 0.93
F7 13 rs491098 112817347 Intronic C G 0.106 0.117 0.39 0.90 0.530 0.93
F10 13 rs3093261 112824083 Near 5UTR T* C 0.460 0.391 6.41 1.33 0.011 0.22
F10 13 rs3211744 112832999 Intronic T G 0.136 0.154 0.85 0.87 0.358 0.83
F10 13 rs2026160 112840894 Intronic C A 0.284 0.258 1.08 1.14 0.298 0.83
F10 13 rs9549675 112846885 Intronic T C 0.205 0.239 2.10 0.83 0.148 0.61
F10 13 rs3211719 112825510 Intronic G A 0.252 0.245 0.09 1.04 0.769 0.93
F10 13 rs3211752 112835460 Intronic G A 0.499 0.489 0.13 1.04 0.716 0.93
F10 13 rs556694 112828042 Intronic C T 0.093 0.089 0.04 1.04 0.836 0.93
F10 13 rs3211770 112841850 Intronic A G 0.109 0.113 0.05 0.96 0.818 0.93
F10 13 rs473598 112849190 Intronic A G 0.128 0.137 0.23 0.92 0.629 0.93
EPCR 20 rs2069948 33226150 Intronic C* T 0.468 0.408 4.72 1.27 0.030 0.22
TFPI 2 rs2192825 188099064 Intronic C T 0.439 0.402 1.81 1.16 0.178 0.66
TFPI 2 rs7594359 188117093 Intronic T C 0.461 0.441 0.52 1.08 0.472 0.93
TFPI 2 rs2192824 188077036 Intronic T C 0.449 0.428 0.54 1.09 0.461 0.93
TFPI 2 rs13424790 188032097 Downstream G T 0.317 0.310 0.08 1.03 0.778 0.93
TFPI 2 rs8176548 188048580 Intronic T C 0.351 0.347 0.02 1.02 0.878 0.93
TFPI 2 rs10187622 188122406 Intronic T C 0.161 0.165 0.03 0.97 0.864 0.93
TFPI 2 rs12613071 188096556 Intronic C T 0.202 0.195 0.09 1.04 0.762 0.93
P-values were determined by the χ2 -test. Alleles for the positive DNA strand (UCSC annotated) are shown. Significantly associated SNPs; bold, and factor V Leiden
(F5 rs6025) and prothrombin G20210A (F2 rs1799963); italic. *Risk alleles for significant SNPs.
Chr: chromosome. OR: Odds ratio as determined for the minor allele with the major allele as reference. FDR: False discovery rate as described by Benjamini and
Hochberg [28].
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SELP (r2 ≥ 0.93). Moreover, in the Regulome database
(RegulomeDB) [30], the F5 rs9332542 and four SNPs in
perfect LD (rs2227245, rs2213872, rs2213873, rs6662176)were annotated as cis-acting expression quantitative trait
loci (eQTL) for F5, and the F10 rs3093261 was predicted
to be an eQTL for the LAMP1 gene encoding lysosome-
associated membrane protein 1 (LAMP-1), located ~175 kb
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none of the SNPs within a 300 bp distance from the near-
est splice site, appeared to affect splicing.
Conditional- and haplotype analysis of the F5 SNPs
associated with breast cancer
In total, four breast cancer associated SNPs were found in
the F5 gene region (rs12120605, rs6427202, rs9332542,
and rs6427199), and the interdependence of these SNPs
on breast cancer risk was investigated (Table 2). The
rs12120605 appeared to represent an independent signal,
as this SNP remained significantly associated after con-
ditioning on the other three F5 SNPs as separate covari-
ates. Moreover, when set as the conditional SNP, the
rs12120605 did not diminish the significance of the
other three SNPs, reflecting the modest pairwise LD
with these SNPs (D’ ≤ 0.50) (Figure 1). In contrast, a de-
pendency appeared to exist between the rs6427202,
rs9332542, and rs6427199 as their effects were neutral-
ized when conditioned on each other. This result, com-
bined with the LD structure between the three SNPs (D’
between 0.35-1.00) (Figure 1), pointed towards a poten-
tial haplotype effect. Indeed, the haplotype consisting
of all three individual risk alleles (C-G-G) was common
in the population (frequency of 0.32), and was found to
be significantly associated with breast cancer (OR 1.39,
P = 0.011). Conditioning on factor V Leiden did not
alter the association of any of the other F5 SNPs (data
not shown).
Relation between hemostatic parameters and breast
cancer
Coagulation activity and levels of coagulation inhibitors
were compared between cases and controls to explore if
any hemostatic abnormalities existed. Median levels and
P-values are provided in Additional file 4: Table S3.
The estimated associations between breast cancer sta-
tus and either high or low levels of the hemostatic pa-
rameters are shown in Table 3. From the CAT assay, an
association with breast cancer was predicted for lag
times and times to peak thrombin below the 10th per-
centile, and for peak thrombin above the 90th percentile,
with ORs ranging from 5.8 to 7.1. ETP above the 90th





rs12120605 1.49 (0.024) -
rs6427202 1.32 (0.021) 1.36 (0.010)
rs9332542 1.32 (0.022) 1.35 (0.014)
rs6427199 1.27 (0.036) 1.33 (0.014)
ORs and P-values are shown before and after conditioning on each of the SNPs. Sigresistance levels above the 90th percentile associated
with breast cancer in factor V Leiden non-carriers (OR
6.5, 95% CI 4.06-10.35), but also in factor V Leiden car-
riers (OR 38.3, 95% CI 6.2-236.6). Moreover, subjects
with high D-dimer levels (>90th percentile) were also as-
sociated with breast cancer disease (OR 2.0, 95% CI
1.26-3.28). No association with breast cancer was found
for low levels of the coagulation inhibitors protein C,
protein S or free TFPI, but for antithrombin activity
below the 10th percentile, the association with breast
cancer was ~6-fold higher compared to activity above
the 10th percentile. None of the associated hemostatic
parameters were specific to the different subsets of pa-
tients, as defined by the ER and PR hormone receptor sta-
tus or triple negative status (Additional file 5: Table S4).
Since increased APC resistance in cancer has been de-
tected in several previous studies, adjustments were
made for the hemostatic parameters that correlated to
APC resistance; protein C (ρ = -0.18, P = 0.003), protein
S (ρ = -0.33, P < 0.001), and free TFPI (ρ = -0.42, P < 0.001).
Adjusting for each of these parameters as separate covari-
ates had only a modest impact on the association between
high APC resistance and breast cancer in factor V Leiden
non-carriers (data not shown), and the OR obtained in the
full model with all covariates included (OR 8.6, 95% CI
5.1-14.3), was similar to that of the unadjusted model in
Table 3 (OR 6.5, 95% CI 4.06-10.35). Equivalent results
were obtained for factor V Leiden carriers (adjusted OR
50.7, 95% CI 6.6-390.9 vs. unadjusted OR 38.3, 95% CI
6.2-236.6 (Table 3)). Age did not correlate to any of the
associated coagulation parameters (assessed in controls),
except for an inverse correlation to APC resistance
(ρ = -0.13, P = 0.032).
Genotype-phenotype associations
In an effort to explain some of the hemostatic alterations
observed in the patients, we searched for possible regu-
latory relationships between the genetic variations and
the hemostatic parameters. Only the hemostatic parame-
ters being significantly altered were considered, and we
explored if any of these parameters were unevenly distrib-
uted across the genotypes of the six breast cancer associ-
ated SNPs in Table 1 (and Additional file 2: Table S1).










1.55 (0.015) 1.54 (0.016) 1.62 (0.009)
- 1.19 (0.218) 1.24 (0.085)
1.20 (0.244) - 1.23 (0.095)
1.22 (0.111) 1.20 (0.141) -
nificant conditional associations are shown in italic.
Figure 1 Linkage disequilibrium (LD) plots of the F5 SNPs. Linkage disequilibrium (LD) plots of the 11 analyzed SNPs including factor V
Leiden (rs6025), within the F5 gene for controls (left plot) and cases (right plot). The LD measure D’ is shown. The disease associated SNPs are
depicted in green.
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http://www.biomedcentral.com/1471-2407/14/845for controls and cases since divergent regulatory mecha-
nisms could exist in the two groups. Two significant cor-
relations were found in the control group; F5 rs6427202
correlated with thrombin peak (Figure 2A), whereas F5
rs6427199 correlated with antithrombin (Figure 2B). Be-
cause high thrombin peak and low antithrombin activity
were found associated with breast cancer (Table 3), we ad-
justed for F5 rs6427202 and F5 rs6427199, respectively.
However, these adjustments did not change the OR esti-
mates obtained in the unadjusted model (data not shown).
Interestingly, a trend for a correlation between the num-
ber of F5 rs6427199 risk alleles and high APC resistance
was found in controls (P = 0.15). F5 rs6427199 may thus
be an interesting candidate for general investigations of
novel APC resistance inducing factors. No genotype-
phenotype correlations were found in the case group.
Discussion
Hypercoagulability is a common, but complex and multi-
factorial phenomenon in cancer. Although involvement of
both clinical and biological aspects is recognized, the pre-
cise mechanism(s) underlying how the hemostatic system
relates to cancer is not clear.
Among the 37 common SNPs in seven TF pathway genes
(TF, F2, F5, F7, F10, TFPI and EPCR), six SNPs in three
separate genes were found to be associated with breast
cancer: four intronic SNPs in the F5 gene (rs12120605,
rs6427202, rs9332542 and rs6427199), one in the up-
stream region of the F10 gene (rs3093261), and one
intronic SNP in the EPCR gene (rs2069948). This is first-
time evidence for an association between these SNPs and
cancer.Since breast cancer is a heterogeneous disease, certain
risk factors may be specific for subsets of patients. In
this study, the SNP in EPCR was associated with patients
positive for ER and PR, while the SNPs in F5 showed a
tendency towards a preferential association with hor-
mone receptor negative patients and triple negative pa-
tients. This might indicate that the F5 SNPs may
influence breast cancer etiology in hormone receptor
negative/triple negative patients.
The association with F5 expression [31] represents a
possible link to the increased coagulation activity in
breast cancer, and F10 rs3093261, located between the
F10 and F7 gene, has been associated with increased
FVII levels in stroke patients [32], which may link F10
rs3093261 to the increased coagulation activation ob-
served in our study.
Supporting a role in cancer, EPCR has shown tumor
growth promoting effects in mice [16].
Notably, the associated F5 SNPs were common variants,
and were independent of factor V Leiden carrier status.
We found no association with factor V Leiden heterozy-
gosity. Although not previously investigated in untreated
breast cancer, studies in gastric- [19], gynaecological- [21],
colorectal- [3], and oral cancer [22,33] support this lack of
association. So far, the study by Vossen et al. is the only
study large enough to investigate the significance of
homozygous factor V Leiden, reporting a 6-fold increased
risk of colorectal cancer in homozygous carriers [18].
Interestingly, a reduced cancer risk (~30%) for heterozy-
gous factor V Leiden carriers was reported in the same
study [18]. Neither did we find a significant association
with the prothrombin G20210A variant. However, given
Table 3 Distribution of cases and controls among the high





OR 95% CI P-value
Coagulation activity:
ETP (%)*
<90th percentile 309 246 Ref. Ref. Ref.
>90th percentile 37 27 1.09 0.65-1.84 0.744
Lag time (%)*
>10th percentile 211 246 Ref. Ref. Ref.
<10th percentile 135 27 5.83 3.71-9.16 <0.001
ttPeak (%)*
>10th percentile 206 249 Ref. Ref. Ref.
<10th percentile 140 24 7.05 4.40-11.29 <0.001
Peak (%)*
<90th percentile 208 246 Ref. Ref. Ref.
>90thpercentile 138 27 6.05 3.85-9.50 <0.001
APC resistance (nAPC-sr)
FV Leiden non-carriers
<90th percentile 190 228 Ref. Ref. Ref.
>90th percentile 135 25 6.48 4.06-10.35 <0.001
FV Leiden carriers
<90th percentile 4 18 Ref. Ref. Ref.
>90th percentile 17 2 38.3 6.2-236.6 <0.001
D-dimer (ng/mL)
<90th percentile 292 246 Ref. Ref. Ref.
>90th percentile 65 27 2.03 1.26-3.28 0.004
Coagulation inhibitors:
AT (%)
>10th percentile 215 246 Ref. Ref. Ref.
<10th percentile 135 27 5.72 3.64-8.99 <0.001
Protein C (%)
>10th percentile 310 246 Ref. Ref. Ref.
<10th percentile 40 27 1.18 0.702-1.97 0.539
Protein S (%)
>10th percentile 325 246 Ref. Ref. Ref.
<10th percentile 22 27 0.62 0.34-1.11 0.106
Free TFPI (ng/mL)
>10th percentile 319 246 Ref. Ref. Ref.
<10th percentile 39 27 1.11 0.66-1.87 0.683
ORs, 95% CI and P-values were obtained by logistic regression with respect to cases.
AT = antithrombin. ttpETP = time to thrombin peak. nAPC-sr = normalised APC
sensitivity ratio. (%) describes activity as compared to pooled normal plasma
(PNP). *CAT-assay variables.
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http://www.biomedcentral.com/1471-2407/14/845the low allele frequency (0.5-1.3%), a larger sample size
would be needed to establish the role of this variant in
breast cancer risk. Correspondingly, other studies across
cancer types did not succeed in finding an association withprothrombin G20210A [3,19,21,22,33]. Pihusch et al. found
an increased risk of gastrointestinal cancer for this variant
[20], while Vossen et al. found a decreased risk of colorec-
tal cancer for prothrombin G20210A heterozygotes [18].
In addition to the SNP discoveries, our study also pro-
vides evidence of a hypercoagulable state in the breast
cancer patients, as detected by the CAT assay and in-
creased APC resistance and D-dimer. The CAT assay pa-
rameters lag time, time to peak thrombin and peak
thrombin were all associated with breast cancer, but not
total ETP. Hence, the combination of the kinetic CAT
parameters is likely to provide a better understanding of
hypercoagulable states than do individual parameters
[34]. Although care should be taken in comparing differ-
ent thrombin assays [35], our CAT assay results are in
line with previous studies in breast cancer reporting in-
creased levels of thrombin formation [2], and shortened
activated partial thromboplastin times (aPTT) [36].
We also found that increased APC resistance was asso-
ciated with breast cancer. This finding is supported by a
former breast cancer study [2], and studies in colorectal-
[3] and gastrointestinal cancer [10]. In line with the exist-
ing literature, levels of protein S, TFPI, and also protein C
correlated inversely to APC resistance [2,37]. However,
these potential APC resistance determinants did not affect
the association between APC resistance and breast cancer.
Interestingly, we found that increased APC resistance was
associated with breast cancer in both carriers and non-
carriers of factor V Leiden. Supported by previous studies
[1,38], this suggests that the acquired APC resistant
phenotype appears more crucial in cancer than APC re-
sistance caused by factor V Leiden. Acquired APC resist-
ance could be due to increased levels of coagulation
factors like factor V and factor VIII [11], yet unidentified
factors produced by tumor- or stimulated host cells, or
novel hereditary causes. Of note, the factor V Cambridge
(rs118203906) variant, previously associated with increased
APC resistance [39], turned out to be monomorphic in
our case subjects (data not shown).
Further demonstrating the procoagulant state, high
levels of the fibrin degradation product D-dimer were
also associated with breast cancer. This confirms previ-
ous studies in breast cancer [6,36,40], and also other
cancers like colorectal- [41], lung- [42] and gastric can-
cer [43]. These studies also demonstrated D-dimer as a
potential important marker in disease stage prediction
and for prognostic purposes. Furthermore, increased
levels of D-dimer in cancer have been detected even in
the absence of thrombosis [44].
Among the coagulation inhibitors, only low levels of
antithrombin were associated with breast cancer. De-
creased antithrombin levels have previously been found
in breast cancer by Nijziel et al. [2], while no difference
was observed either in another breast cancer study [45],
Figure 2 Significant genotype-phenotype correlations. Significant genotype-phenotype correlations in the control group after pairwise
comparison analyzed by the Mann Whitney U test. Tests with ≥1 significant Bonferroni corrected P-value(s) are shown. (Bonferroni corrected
P; 0.05/9 = 0.006). Distribution of (A) Peak (%) across the genotypes of F5 rs6427202, and (B) antithrombin (%) across the genotypes of F5
rs6427199. The box and whiskers plots show the minimum, 25th percentile, median, 75th percentile and maximum levels of the hemostatic
parameters plotted against the genotype of the SNPs. The risk alleles of the SNPs are underlined.
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http://www.biomedcentral.com/1471-2407/14/845a study on colorectal- [3] or a study on advanced can-
cers [1]. Supporting our observations, the two latter
studies also found that neither protein S nor protein C
levels in patients deviated from healthy controls. In a
study of gastrointestinal cancer, Lindahl et al. found that
the activity of antithrombin and protein C decreased [8],
while the TFPI activity increased as the cancer pro-
gressed. Later, Iversen et al. confirmed that the median
levels of TFPI activity were above the upper normal limit
in gastrointestinal- and lung cancer, and in metastatic
patients. In contrast, median TFPI activity in breast can-
cer was within the normal range [9]. Comparable to the
latter, we found no difference in levels of TFPI in the
cases compared to controls. Thus, the TFPI levels may
vary according to cancer type and disease stage.
Noteworthy, the hypercoagulability did not seem to
depend on hormone receptor status, as the estimated as-
sociations between breast cancer and the hemostatic
plasma markers were not significantly different between
hormone receptor negative or triple negative patients
and patients with other subtypes. This observation is in
agreement with a recent breast cancer study that did not
observe any variation in D-dimer, prothrombin times
(PT), and aPTT according to ER or PR status [36].
Since breast cancer is among the cancers with the low-
est risk of thrombosis [46], our study indicates that
activated coagulation may reflect the biology of the
underlying tumor and could be an important indicator
of cancer progression. In this context, it should be em-
phasized that the herein retrospective data is only suited
to assess the presence of a hypercoagulable state in pa-
tients already diagnosed with breast cancer. Prospective
studies are needed to establish whether coagulation acti-
vation precedes breast tumor development, or if itmirrors the course of the established disease. Interest-
ingly, a prospective study reported a ~3-fold increased
rate of digestive tract cancers in men with persistent co-
agulation activation [47].
The present work represents the most comprehen-
sive study to investigate hemostasis in a homogenous
(Scandinavian) breast cancer material. The tag SNP selec-
tion ensures good coverage of the normal genetic diversity
within each selected gene. In this respect, it should be
noted that our SNP associations may be a reflection of LD
with other known or yet unknown true causal variants. In
order to verify the significance of the associated SNPs, our
findings should be validated in a different study popula-
tion and other cancer types.
One limitation of the study is that the breast cancer
patients were older than the control women, thus, an age-
related bias could exist for the comparison of hemostatic
plasma markers between patients and controls. Although
supported by the existing literature, these results should
therefore be interpreted with some caution. On the other
hand, the inclusion criteria eliminate a possible effect of
anticoagulant- or hormone therapy, and pregnancy, as well
as chemotherapy, on the hemostatic parameters.
Conclusions
This study has established the existence of a global pro-
coagulant profile in breast cancer patients. The coagulation
activity seemed to be independent of factor V Leiden and
prothrombin G20210A. Instead, novel associations between
common SNPs in genes of the TF pathway (F5, F10, and
EPCR) and breast cancer susceptibility were demonstrated.
Based on both phenotypic and genotypic evidence, this
study supports the importance of developing new thera-
peutic strategies targeting coagulation processes in cancer.
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Additional file 1: Figure S1. TF-pathway of coagulation. The TF-FVIIa
complex initiates the coagulation cascade by activating FX to FXa, which
aided by its cofactor FVa cleaves prothrombin to generate thrombin.
Thrombin cleaves fibrinogen to form fibrin monomers that together with
activated platelets form a blood clot. D-dimer is a fibrin degradation
product. Coagulation inhibitors and their targets are designated. EPCR has
been indicated to associate with the TF-FVIIa complex. The FVL (rs6025)
polymorphism prevents the ability of aPC to cleave and inhibit FVa, causing
(inherited) APC resistance. The PT G20210A (rs1799963) polymorphism
increases the rate of prothrombin protein production. Regular arrows and
blunt-end arrows illustrate activation and inhibition, respectively. The
hemostatic markers measured in plasma in this study are shaded in grey.
EPCR = endothelial protein C receptor, TF = tissue factor, FVIIa = activated
factor VII, FX = factor X, FXa = activated factor X, FVa = activated factor Va,
TFPI = tissue factor pathway inhibitor, PS = protein S, aPC = activated protein
C, AT = antithrombin, PT = prothrombin, FVL = factor V Leiden, APCR =
activated protein C resistance.
Additional file 2: Table S1. Genotype distributions of the significant
SNPs in TF pathway genes in cases and controls. ORs, 95% CI and P-values
determined with respect to the risk allele (bold) using logistic regression
(additive model). Alleles for the positive DNA strand (UCSC annotated) are
shown.
Additional file 3: Table S2. The breast cancer associated SNPs stratified
by hormone receptor status (ER and PR) and triple negative status (ER
negative/PR negative/HER2 negative) (additive model in binary logistic
regression). ORs determined with respect to the risk allele. Significant
associations are shown in bold.
Additional file 4: Table S3. Plasma levels of hemostatic parameters in
cases and controls. Median values with IQR shown in brackets.
Additional file 5: Table S4. ORs and P-values for hemostatic
parameters stratified by hormone receptor status (ER and PR) and triple
negative status (ER negative/PR negative/HER2 negative).
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